24/7 Customer Support

Press Release

Idiopathic Pulmonary Fibrosis Market Study: A Conceptual Insight into the Pervasiveness of Disease and its Existing and Prospective Curative Options

Idiopathic pulmonary fibrosis (IPF) is a type of chronic lung illness that causes permanent pulmonary function loss due to progressive scarring and fibrosis of the lungs. The Global Idiopathic Pulmonary Fibrosis market is broadly affected by the growing generic population. Studies have shown that the incidence of IPF among the young population ranges between 5-6 cases in 1,00,000 people annually, whereas 11 cases in aged 1,00,000 people. Despite recent advancements in the treatment of various forms of pulmonary fibrosis, there are still numerous gaps in understanding of the disease's natural history, pathogenesis, and management. The research funds will be used to solve these issues and improve patient care around the world. Multiple players have recently become involved in the development of innovative drugs or therapeutics to treat IPF. 

The Global Idiopathic Pulmonary Fibrosis market generated US$1,768.8 million in revenue in 2019 and is projected to reach US$2,859.8 million by 2025 and to US$ 4,298.8 million by 2030, growing at a CAGR of 9.4% from 2019 to 2030.

The factors such as the rapidly increasing aging population and the rise in smoker’s population across the globe are projected to push the market growth higher. It has been found that new IPF cases are typically identified and progressed in the elderly population, whereas the prevalence of the disease is typically low in the group aged 18 to 60 years. Smoking is a significant risk factor linked to the development of IPF. In addition, smoking tobacco is linked to higher mortality risk in IPF patients. According to the Centres for Disease Control and Prevention (CDC), more than 16 million Americans are affected by diseases linked to or induced by smoking. 

However, IPF has a number of diagnostic problems, as well as a number of co-morbidities and a poor prognosis. Because IPF is a relatively rare condition, healthcare expenses are high and disproportionate to the disease's frequency. Comorbidities linked with IPF not only complicate treatment efforts but also add to the burden for patients by increasing expenditures and resulting in poor health outcomes. The high expense of medications used to treat idiopathic pulmonary fibrosis prevents individuals from using or continuing to use them. In addition, the rise in overall medical costs, both for inpatient and outpatient treatments, makes it more difficult for patients to embrace therapy. The high cost of IPF therapy is projected to have a negative impact on the overall market growth.

The market comprises different drug types available for Idiopathic Pulmonary Fibrosis including MAPK inhibitors, tyrosine kinase inhibitors, and autotaxin inhibitors. Esbriet (MAPK Inhibitor) by F. Hoffman La Roche and Ofev (Tyrosine Kinase Inhibitor) by Boehringer Ingelheim International GmbH are the only drugs approved by the Food and Drug Administration (FDA) for the treatment of IPF. Both these drugs slow down the death rate in patients suffering from IPF. MAPK Inhibitors (Esbriet) has the largest market share across drug classes. However, Tyrosine Kinase Inhibitors (OFEV) is expected to grow in the market over the forecast period owing to the priority review by the FDA.

To read more, click and submit a sample request

The regional analysis of the global Idiopathic pulmonary fibrosis market covers the total prevalent population and total diagnosed prevalent population on the basis of age and gender for Idiopathic pulmonary fibrosis in 7MM regions. The US is the leading region in the IPF treatments market in 2018, due to increasing prices of the drugs, accelerated approvals of the drugs in the country, and increasing prevalence of IPF.

InterMune created Esbriet for usage in the United States, Europe, and other nations. In 2011, the European Union (EU) granted commercial permission for the treatment of people with mild to moderate IPF. Another prescription medicine, OFEV was developed by Boehringer Ingelheim Pharma GmbH and Co. Kg whose active ingredient nintedanib is a tyrosine kinase inhibitor (TKI) that inhibits the growth factor receptors involved in the progress of pulmonary fibrosis.

Other key players in the idiopathic pulmonary fibrosis market include Genentech, Inc., Boehringer Ingelheim Pharma GmbH, and Co. Kg, F. Hoffmann-La Roche, FibroGen, Inc., Promedior, Inc., Merck & Co., Inc., Galapagos NV, Biogen, Bristol-Myers Squibb Company, Prometic Life Sciences Inc., and others. On the basis of regional segment, the global Idiopathic Pulmonary Fibrosis Market is segmented as:

  • By Region
    • The U.S.
    • EU5
      • UK
      • France
      • Germany
      • Spain
      • Italy
    • Japan

The expanding number of IPF cases, combined with increased awareness, has fuelled the demand for therapy. Some well-known players include:

  • Genentech, Inc.
  • Boehringer Ingelheim Pharma GmbH and Co. Kg
  • F. Hoffmann-La Roche
  • FibroGen, Inc.
  • Promedior, Inc.
  • Merck & Co., Inc.
  • Galapagos NV
  • Biogen
  • Bristol-Myers Squibb Company
  • Prometic Life Sciences Inc.
{